<DOC>
	<DOCNO>NCT02343289</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability pharmacokinetics esketamine administer intranasal ( administer nose ) oral route evaluate effect clarithromycin pharmacokinetics intranasally administer esketamine .</brief_summary>
	<brief_title>A Study Evaluate Absolute Bioavailability Intranasal Oral Esketamine Effects Clarithromycin Pharmacokinetics Intranasal Esketamine Healthy Participants</brief_title>
	<detailed_description>This single-center , 4-period , fixed-sequence , open-label study . The study consist Screening Period ( Days -21 -2 ) , Open-label Treatment Period 1 , 2 , 3 , 4 End Study ( 9 13 day final dose Early Withdrawal ) . The total duration study 98 day . For 4 period , participant admit study center Day -1 treatment period receive 28 milligram ( mg ) ( intravenous ) 84 mg ( oral intranasal ) esketamine dose regimen Day 1 period fix sequence . Participants also receive 500 mg clarithromycin period 4 . Blood sample collect evaluate pharmacokinetic parameter . Participants ' safety monitor throughout study .</detailed_description>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>For woman childbearing potential , must negative serum betahuman chorionic gonadotropin ( hCG ) pregnancy test screening ; negative urine pregnancy test Day 1 Period 1 If man , must agree use adequate contraception method deem appropriate investigator ( example , vasectomy , doublebarrier , partner use effective contraception ) donate sperm study 3 month receive last dose study drug Participants body mass index ( BMI ) 18 30 kilogram per square meter ( kg/m^2 ) ( inclusive ) , body weight less 50 kg Participants blood pressure ( participant supine 5 minute ) 90 140 millimeter mercury ( mmHg ) systolic , inclusive , high 90 mmHg diastolic Participants comfortable selfadministration intranasal medication able follow instruction provide Participants diagnosed psychiatric disorder include limited psychotic , bipolar , major depressive , anxiety disorder Participants clinically significant medical illness include ( limited ) cardiac arrhythmia cardiac disease , hematologic disease , coagulation disorder ( include abnormal bleeding blood dyscrasia ) , lipid abnormality , significant pulmonary disease , include bronchospastic respiratory disease , diabetes mellitus , renal hepatic insufficiency , thyroid disease , neurologic disease , infection , hypertension vascular disorder , kidney urinary tract disturbance , sleep apnea , myasthenia gravis , illness investigator considers exclude participant could interfere interpretation study result Participants clinically significant abnormal value hematology , clinical chemistry ( particularly potassium magnesium level normal laboratory range ) , urinalysis screen admission study center ( Day 1 Period 1 ) deem appropriate investigator Participants clinically significant abnormal physical examination vital sign screen admission study center ( Day 1 Period 1 ) deem appropriate investigator Participants history drug alcohol abuse disorder within past 1 year , reason believe participant history</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Healthy</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Esketamine</keyword>
	<keyword>JNJ-54135419</keyword>
</DOC>